Townsville Hospital
Welcome,         Profile    Billing    Logout  
 50 Trials 
93 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Collins, Michael T
NCT06474273: TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

Not yet recruiting
4
540
Canada, RoW
Methylprednisolone, IV MP, Prednisone
University of Sydney, University of Manitoba
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
12/29
12/29
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
07/25
04/26
BEAT-Calci, NCT05018221: Better Evidence and Translation for Calciphylaxis

Recruiting
3
350
RoW
Vitamin K1, Phytonadione, Magnesium citrate, Sodium Thiosulfate, Intravenous Sodium Thiosulfate Injection, High Flux Dialyser, High Flux Hemodialysis, Medium Cut-off Dialyser, Medium Cut-off Hemodialysis, Placebo injection (normal saline), 0.9% sodium chloride solution, Placebo capsule (Vitamin K1), Matching placebo capsule, Placebo tablet (Magnesium citrate), Matching placebo tablet
University of Sydney, Australasian Kidney Trials Network, Northern Care Alliance NHS Foundation Trust, Waitemata District Health Board
Calciphylaxis
12/29
12/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT05735015: Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgical Hypoparathyroidism (PSH)

Recruiting
2
30
US
encaleret
National Institute of Dental and Craniofacial Research (NIDCR)
Post-Surgical Hypoparathyroidism
12/25
12/25
VARVARA, NCT05907096: ARGX-117 in Deceased Donor Kidney Transplant Recipients At Risk for Delayed Graft Function

Recruiting
2
102
Europe, Canada, US, RoW
ARGX-117, Placebo
argenx
Delayed Graft Function
04/26
12/26
FUSE-UK, NCT05708963: The U.K. Embryologist Fatigue Study

Completed
N/A
123
US
TMRW Life Sciences, Dudley Associates Healthcare Marketing & Communications
Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain, Back Pain, Neck Pain, Headache, Dizziness, Sleep Disturbance, Chest Pain, Syncope, Cardiovascular Diseases, Shortness of Breath, Gastrointestinal Diseases
01/23
02/23
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
12/23
06/27
T-MD, NCT04549532: Targeted Multidomain () Interventions for Complex Mild Traumatic Brain Injury (mTBI)

Active, not recruiting
N/A
169
US
Targeted Multidomain, Behavioral Management
University of Pittsburgh, Inova Health Care Services, United States Department of Defense
Concussion, Mild
04/25
10/25
VIRTU, NCT06632691: Virtual Reality Headset and Acceptability of Rectosigmoidoscopy in Ulcerative Colitis: a Randomised Controlled Trial

Recruiting
N/A
100
Europe
Virtual reality headset
Centre Hospitalier Departemental Vendee
Haemorrhagic Rectocolitis
04/27
04/27
BHI, NCT04708613: University of Pittsburgh Brain Health Initiative

Recruiting
N/A
300
US
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, Continuous arterial pressure, PET brain imaging, [C-11]6-OH-BTA-1, Pittsburgh Compound B, [F-18]AV-1451, [F-18]T807, LY3191748
David Okonkwo, MD, PhD, National Football League Scientific Advisory Board, Avid Radiopharmaceuticals, Inc., Harvard University
Traumatic Brain Injury
12/25
12/25
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Obermair, Andreas
ACTRN12608000019303: Laparoscopic Approach to Cervical Carcinoma

Recruiting
3
740
 
M.D Anderson Cancer Centre, Queensland Centre for Gynecological Cancer
Cervical Cancer
 
 
ACTRN12606000261516: LACE – Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial

Recruiting
3
755
 
Qld Centre for Gynaecological Cancer, Qld Cancer Fund, Cancer Council (NSW, WA, VIC), Tyco, Johnson & Johnson, Genentech, NHMRC, QUEENSLAND HEALTH, Cancer Australia, Cancer Australia
Endometrial Adenocarcinoma - FIGO Stage 1
 
 
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
01/31
feMMe, NCT01686126: Improving the Treatment for Women With Early Stage Cancer of the Uterus

Active, not recruiting
2
165
RoW
Levonorgestrel, Mirena, Metformin
Queensland Centre for Gynaecological Cancer, The University of Queensland, Queensland University of Technology
Complex Endometrial Hyperplasia With Atypia, Grade 1 Endometrial Endometrioid Adenocarcinoma
10/22
12/26
SATELLITE, NCT06278857: Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Recruiting
2
10
RoW
Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI], JEMPERLI
Queensland Centre for Gynaecological Cancer, GlaxoSmithKline Research & Development Limited
Endometrial Cancer Stage I, Mmr Deficiency, Endometrioid Endometrial Adenocarcinoma, Immune-related Adverse Event
06/26
06/28
ANVU, NCT06476639: Australian National Vulvar Cancer Trial

Not yet recruiting
2
240
RoW
High-resolution bilateral groin ultrasound monitoring
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital
Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node, Ultrasound Therapy; Complications
04/27
04/29
NODE, NCT06264167: (groiN ultrasOunD cancEr)

Recruiting
N/A
30
RoW
High-resolution bilateral groin ultrasound surveillance
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital
Vulvar Cancer Stage Ib, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node, Ultrasound Therapy; Complications
03/26
03/28
ACTRN12610000547044: Early postoperative enteral feeding in patients with advanced epithelial ovarian cancer

Active, not recruiting
N/A
120
 
Queensland Centre for Gynaecological Cancer, Cancer Australia, Gallipoli Research Foundation, Wesley Research Institute
Primary epithelial ovarian cancer, Primary fallopian tube cancer, Primary peritoneal cancer, moderate malnourishment, severe malnourishment, Postoperative enteral feeding
 
 
Land, Russell
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
01/31
Chetty, Naven
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
01/31
ANVU, NCT06476639: Australian National Vulvar Cancer Trial

Not yet recruiting
2
240
RoW
High-resolution bilateral groin ultrasound monitoring
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital
Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node, Ultrasound Therapy; Complications
04/27
04/29
Lellouche, Francois
REVISE, NCT03374800 / 2020-000483-27: Re-EValuating the Inhibition of Stress Erosions () Trial

Completed
3
4800
Europe, Canada, US, RoW
Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Gastrointestinal Hemorrhage (Clinically Important, Upper)
10/23
01/24
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
NCT05587686: Potential Impact of the Use of the Application VentilO

Active, not recruiting
N/A
100
Canada
VentilO application
Laval University
Mechanical Ventilation Complication
06/25
12/25
Oxygap pong, NCT05590130: Comparison of Two Oxygenation Targets With Two Different Oximeters - Impact on Oxygen Flow Rates and Oxygenation

Recruiting
N/A
40
Canada
Manual Oxygen titration with Philips oximeter (SpO2 target 90%), Manual oxygen titration with Nonin oximeter (SpO2 target 90%), Manual Oxygen titration with Philips oximeter (SpO2 target 94%), Manual oxygen titration with Nonin oximeter (SpO2 target 94%)
Laval University
Oxygen Toxicity, Respiratory Failure
12/24
06/25
Ventilo, NCT04390360: Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction

Recruiting
N/A
20
Canada
Protective ventilation implementation, Protective ventilation with HME, Protective ventilation with Heated humidifier, Tidal Volume reduction
Laval University
ARDS, Human, Mechanical Ventilation Complication, Humidifier Lung
12/23
06/24
OxyGap, NCT04772183: : Comparison Between Different Pulse Oximeter and With the Arterial Blood Gase

Recruiting
N/A
300
Canada
SpO2 and SaO2 comparison
Laval University
Respiratory Failure, Hypoxemia, Hyperoxemia
12/24
06/25
Oxygap 2, NCT06102499: Comparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study

Recruiting
N/A
200
Canada
SpO2 and SaO2 comparison
Laval University
Respiratory Failure, Hypoxemia, Hyperoxemia
06/25
12/25
NCT06719258: Evaluation of Gas Humidification Practices in Patients Under Invasive Mechanical Ventilation

Recruiting
N/A
40
Canada
MR850, FP950
Laval University
Humidifier Lung, Mechanical Fragility, Respiratory Complication
06/25
12/25
FreeO2 HypHop, NCT03835741: Automated Adjustment of Oxygen on Patient With Acute COPD Exacerbation -

Recruiting
N/A
102
Canada
FreeO2, manual titration
Laval University
Oxygen Toxicity, COPD Exacerbation, Hyperoxia, Hypoxemia, Hypoxic Respiratory Failure
12/25
06/26
NCT03396172: FreeDom: Innovative Strategy for the Management of COPD Exacerbations

Recruiting
N/A
100
Canada
Control, Usual oxygen administration and usual hospitalization, FreeDom, Early Hospital discharge with home hospitalisation
Laval University
Oxygen Deficiency, COPD Exacerbation
06/25
12/25
Turgeon, Alexis F
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
VICToRY, NCT04138394: VItamin C in Thermal injuRY: The Trial

Recruiting
3
666
Europe, Canada, US, RoW
Ascorbic Acid, vitamin C, placebo, saline, D5W
Clinical Evaluation Research Unit at Kingston General Hospital, Dr. Christian Stoppe, MD, Co-Principal Investigator, Wurzburg University, Wurzburg, Germany
Shock, Thermal Burn
12/26
06/27
ATTACC-CAP, NCT05848713: AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting
3
4000
Canada, US, RoW
Heparin
University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI
Community-acquired Pneumonia
03/28
03/29
CINERGY, NCT05148715: Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function

Recruiting
2
414
Canada
Tacrolimus, Prograf, Placebo
Université de Sherbrooke, McMaster University
Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury
01/25
01/26
NCT04291235: The NEUROlogically-impaired Extubation Timing Trial (NEURO-ETT)

Not yet recruiting
N/A
332
Canada
Airway Management Pathway, Usual Care
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Acute Brain Injury
01/23
01/23
HEMOTION, NCT03260478: HEMOglobin Transfusion Threshold in Traumatic Brain Injury OptimizatioN: The Trial

Completed
N/A
742
Europe, Canada, RoW
Red Blood Cells Transfusion
CHU de Quebec-Universite Laval, Canadian Critical Care Trials Group, Canadian Traumatic Brain Injury Research Consortium, Canadian Institutes of Health Research (CIHR), Canadian Perioperative Anesthesia Clinical Trials (PACT) Group
Traumatic Brain Injury, Transfusion
10/23
02/24
NeurO2, NCT04935866: Optimal Brain Oxygenation in Neurologic Intensive Care Unit : The Study

Recruiting
N/A
286
Canada
Near-infrared spectroscopy (NIRS)
CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Canadian Critical Care Trials Group, Canadian Traumatic Brain Injury Research Consortium
Traumatic Brain Injury, Subarachnoid Hemorrhage, Brain Injuries, Near-Infrared Spectroscopy, Intensive Care Neurological Disorder, Anemia
07/24
07/25
OLEXT-3, NCT06296173: Open Lung Protective Extubation Following General Anesthesia

Recruiting
N/A
270
Canada
Protective "open-lung" extubation, Conventional extubation
Centre hospitalier de l'Université de Montréal (CHUM), CHU de Quebec-Universite Laval, The Ottawa Hospital, University Health Network, Toronto, Canadian Institutes of Health Research (CIHR)
Intra-abdominal Surgery, Anesthesia, Lung Injury, Ventilator-Induced Lung Injury, Atelectasis
12/25
04/26
TAN, ALEXANDER TONG BOON
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
IMPRESSION, NCT04409912: Sirolimus Coated Angioplasty Versus Plain Balloon Angioplasty

Recruiting
N/A
170
RoW
Sirolimus coated balloon, Plain balloon
Singapore General Hospital, National University Hospital, Singapore, Sengkang General Hospital
End Stage Renal Failure on Dialysis, Arteriovenous Graft Occlusion
10/23
10/24
Garrett, Andrea
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
01/31
ANVU, NCT06476639: Australian National Vulvar Cancer Trial

Not yet recruiting
2
240
RoW
High-resolution bilateral groin ultrasound monitoring
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital
Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node, Ultrasound Therapy; Complications
04/27
04/29
CCTG EN10, NCT05640999: Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Recruiting
2
325
Europe, Canada, US, RoW
Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation
Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network
Endometrial Cancer
12/28
06/29
NODE, NCT06264167: (groiN ultrasOunD cancEr)

Recruiting
N/A
30
RoW
High-resolution bilateral groin ultrasound surveillance
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital
Vulvar Cancer Stage Ib, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node, Ultrasound Therapy; Complications
03/26
03/28
Nicklin, James
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
01/31
Perrin, Lewis
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
01/31
ANVU, NCT06476639: Australian National Vulvar Cancer Trial

Not yet recruiting
2
240
RoW
High-resolution bilateral groin ultrasound monitoring
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital
Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node, Ultrasound Therapy; Complications
04/27
04/29
Zielinski, Robert
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
MOST-CIRCUIT, NCT04969887: Combination Immunotherapy in Rare Cancers Under InvesTigation

Active, not recruiting
2
240
RoW
Ipilimumab, YERVOY ®, Nivolumab, Opdivo
Olivia Newton-John Cancer Research Institute, Bristol-Myers Squibb
Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor
03/26
03/28
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

Completed
1
6
RoW
A:YH002+YH001, B:YH002+YH001, YH002+YH001
Eucure (Beijing) Biopharma Co., Ltd
Advanced Solid Tumor
07/23
07/23
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
FRAILPOL, NCT04518423: Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People

Recruiting
N/A
1093
Europe
The Opole University of Technology
Frailty, Frailty Syndrome, Frail Elderly Syndrome, Fragility, Aging, Aging Problems, Aging Disorder, Aging Well
12/26
12/26
Hiwase, Devendra
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
KER050-MD-201, NCT04419649 / 2021-001838-19: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Hourglass Dec 2024 - Dec 2024 : Additional data for very low, low, or intermediate risk myelodysplastic syndrome
Hourglass Jul 2023 - Dec 2023 : Enrollment completion of transfusion dependent cohorts of trial for low, or intermediate risk MDS
Recruiting
2
140
Europe, US, RoW
KER-050
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Myelodysplastic Syndromes, Cytopenia
06/25
11/25
Varma, Suresh
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Briscoe, Karen
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

Withdrawn
2
80
Europe, RoW
YH001 + Toripalimab
Eucure (Beijing) Biopharma Co., Ltd
HCC, NSCLC Stage IIIB, NSCLC Stage IV
12/24
03/25
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
GoTHAM, NCT04261855: Targeted Therapy and Avelumab in Merkel Cell Carcinoma

Recruiting
1/2
19
RoW
Avelumab, Bavencio, Anti-PD-L1, External Beam Radiation Therapy (EBRT), Radiotherapy, Lutetium-177 (177Lu)-DOTATATE, Peptide Receptor Radionuclide Therapy (PRRT), Lutathera
Melanoma and Skin Cancer Trials Limited
Metastatic Merkel Cell Carcinoma
07/27
07/27
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Eastgate, Melissa
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients with Stage I-III Merkel Cell Carcinoma

Recruiting
2
120
RoW
Avelumab, anti-PD-L1, Bavencio, Placebo
Melanoma and Skin Cancer Trials Limited
Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin
04/27
04/30
Joshi, Abhishek
ICON9, NCT03278717 / 2017-000161-75: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London, Cancer Research UK, AstraZeneca UK Limited
Ovarian Cancer
12/23
12/23
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
Lai, Hock-Choong
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
Chilkuri, Madhavi
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients with Stage I-III Merkel Cell Carcinoma

Recruiting
2
120
RoW
Avelumab, anti-PD-L1, Bavencio, Placebo
Melanoma and Skin Cancer Trials Limited
Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin
04/27
04/30
ACTRN12618000165280: Smoking cessation and effects of cigarette smoking on cure and side effects of treatment in patients with cancer in the head and neck region.

Recruiting
N/A
156
 
MADHAVI CHILKURI, Study, Education and Research Trust Funding, Townsville Hospital
Head and Neck Squamous Cell Cancer, Cigarette smoking
 
 
Doyle, Rachel
KEYPAD, NCT03280667: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Active, not recruiting
2
59
RoW
Pembrolizumab plus denosumab, Keytruda and Xgeva
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Merck Sharp & Dohme LLC, Amgen
Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer
06/23
06/23
DECREASE, NCT04319783: Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Recruiting
2
70
RoW
Darolutamide, NUBEQA, Bayer HealthCare Pharmaceuticals Inc., Radiotherapy
Trans Tasman Radiation Oncology Group, Bayer, Peter MacCallum Cancer Centre, Australia
Advanced Prostate Carcinoma, Cancer of Prostate, PSA, Castrate Resistant Prostate Cancer
06/26
06/26
Srivastava, Vikas
AKTN16.01, NCT04939935: Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Recruiting
3
1174
RoW
Metformin XR, APO-Metformin XR (500mg), Control, Placebo
The University of Queensland
Autosomal Dominant Polycystic Kidney Disease
12/26
05/27
BEAT-Calci, NCT05018221: Better Evidence and Translation for Calciphylaxis

Recruiting
3
350
RoW
Vitamin K1, Phytonadione, Magnesium citrate, Sodium Thiosulfate, Intravenous Sodium Thiosulfate Injection, High Flux Dialyser, High Flux Hemodialysis, Medium Cut-off Dialyser, Medium Cut-off Hemodialysis, Placebo injection (normal saline), 0.9% sodium chloride solution, Placebo capsule (Vitamin K1), Matching placebo capsule, Placebo tablet (Magnesium citrate), Matching placebo tablet
University of Sydney, Australasian Kidney Trials Network, Northern Care Alliance NHS Foundation Trust, Waitemata District Health Board
Calciphylaxis
12/29
12/29
Win, April
NCT03793257: The EXCEL Registry of Patients Requiring ECMO

Recruiting
N/A
3000
RoW
Australian and New Zealand Intensive Care Research Centre, National Health and Medical Research Council, Australia, Extracorporeal Life Support Organization, National Heart Foundation, Australia, The Alfred, Barwon Health, Fiona Stanley Hospital, The Prince Charles Hospital, Royal Prince Alfred Hospital, Sydney, Australia, St Vincent's Hospital, Sydney
Critically Ill, Acute Respiratory Failure, Acute Heart Failure, Cardiac Arrest
12/26
12/27
Kan, George
NCT04538157: Comprehensive Geriatric Assessment for Frail Older People With Chronic Kidney Disease - The GOAL Trial

Completed
N/A
240
RoW
Comprehensive Geriatric Assessment, CGA
The University of Queensland, National Health and Medical Research Council, Australia
Frailty, Chronic Kidney Diseases
06/24
11/24
Lai, Choong
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Hill, A/Prof Jonathon
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients with Stage I-III Merkel Cell Carcinoma

Recruiting
2
120
RoW
Avelumab, anti-PD-L1, Bavencio, Placebo
Melanoma and Skin Cancer Trials Limited
Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin
04/27
04/30

Download Options